Injection of [99mTc]Tc-ZHER2:4107, SPECT/CT
Phase 2
Injection of [99mTc]Tc-ZHER2:4107, SPECT/CT is one of 3 therapeutic programs targeting Primary Breast Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in Primary Breast Cancer
#DrugCompanyPhaseTrials
1SHR-A1811
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Trastuzumab Emtansine
SSeoul National University Bundang Hospital
Phase 3
Injection of [99mTc]Tc-ZHER2:4107, SPECT/CT
TTomsk National Research Medical Center of the Russian Academy of Sciences
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Primary Breast Cancer1 trial
SPECT/CT Imaging of Different Types of HER2 Expression in Breast Cancer Using Technetium-99m-labelled Affibody [99mTc]Tc -ZHER2:4107
Enrolling by invitation·TTomsk National Research Medical Center of the Russian Academy of Sciences·Phase 2·NCT07292571·50 enrolled
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]